144 related articles for article (PubMed ID: 5030810)
1. Evaluation of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962) in the management of patients with advanced breast cancer.
Ahmann DL; Hahn RG; Bisel HF
Cancer Chemother Rep; 1972 Feb; 56(1):93-4. PubMed ID: 5030810
[No Abstract] [Full Text] [Related]
2. Combined therapy with cytosine arabinoside (NSC-63878) and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962) for advanced solid tumors.
Kinne DW; Humphrey EW
Cancer Chemother Rep; 1972 Feb; 56(1):53-9. PubMed ID: 5030809
[No Abstract] [Full Text] [Related]
3. Phase II study of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962) in the treatment of bronchogenic carcinoma.
Olshin S; Siddiqui S; Firat D
Cancer Chemother Rep; 1972 Apr; 56(2):259-61. PubMed ID: 5043228
[No Abstract] [Full Text] [Related]
4. Treatment of advanced Hodgkin's disease with (1,3 bis (2-chloroethyl)-1-nitrosourea) BCNU.
Young RC; DeVita VT; Serpick AA; Canellos GP
N Engl J Med; 1971 Aug; 285(9):475-9. PubMed ID: 5558887
[No Abstract] [Full Text] [Related]
5. 5-Fluorouracil (5-Fu; NSC-19893), 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388), vincristine (NSC-67574), and 1,3-bis(2-chloroethyl)-2-nitrosourea (BCNU; NSC-409962) given concomitantly in the treatment of solid tumors in man.
van Eden EB; Falkson G; van Dyk JJ; van der Merwe AM; Falkson HC
Cancer Chemother Rep; 1972 Feb; 56(1):107-47. PubMed ID: 5030803
[No Abstract] [Full Text] [Related]
6. Treatment of Hodgkin's disease and other cancers with 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962).
Marsh JC; DeConti RC; Hubbard SP
Cancer Chemother Rep; 1971 Dec; 55(5):599-606. PubMed ID: 4334161
[No Abstract] [Full Text] [Related]
7. 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962) given concomitantly with cytosine arabinoside (NSC-63878) in the treatment of cancer.
van Eden EB; Falkson HC; Falkson G
Cancer Chemother Rep; 1970 Oct; 54(5):347-59. PubMed ID: 5514624
[No Abstract] [Full Text] [Related]
8. Nitrosoureas: 1,3-bis(2-chloroethyl)-1-nitrosourea (NSC-409962; BCNU) and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (NSC-79037; CCNU)--clinical brochure.
Carter SK; Newman JW
Cancer Chemother Rep 3; 1968 Dec; 1(1):115-51. PubMed ID: 4917773
[No Abstract] [Full Text] [Related]
9. Enhancement of the antitumor effect of 1,3-bis(2-chloroethyl)-1-nitrosourea by vitamin A and caffeine.
Cohen MH
J Natl Cancer Inst; 1972 Apr; 48(4):927-32. PubMed ID: 5023690
[No Abstract] [Full Text] [Related]
10. BCNU (1,3-bis(2-chloroethyl)-1-nitrosourea; NSC-409962) in the treatment of malignant brain tumor--a preliminary report.
Walker MD; Hurwitz BS
Cancer Chemother Rep; 1970 Aug; 54(4):263-71. PubMed ID: 4946011
[No Abstract] [Full Text] [Related]
11. Sequential 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (NSC 79037) and 5-fluorouracil (NSC 19893) therapy of gastrointestinal cancer.
Moertel CG; Schutt AJ; Reitemeier RJ; Hahn RG
Cancer Res; 1972 Jun; 32(6):1280-2. PubMed ID: 5030827
[No Abstract] [Full Text] [Related]
12. Treatment of mycosis fungoides with topical nitrosourea compounds.
Zackheim HS
Arch Dermatol; 1972 Aug; 106(2):177-82. PubMed ID: 5048217
[No Abstract] [Full Text] [Related]
13. 1,3-bis (2-chloroethyl)-1-nitrosourea (NSC-409962) in the treatment of brain tumors.
Wilson CB; Boldrey EB; Enot KJ
Cancer Chemother Rep; 1970 Aug; 54(4):273-81. PubMed ID: 4334089
[No Abstract] [Full Text] [Related]
14. Success and failure in the treatment of solid tumors. 3. "Cure" of metastatic Lewis lung carcinoma with methyl-CCNU (NSC-95442) and surgery-chemotherapy.
Mayo JG; Laster WR; Andrews CM; Schabel FM
Cancer Chemother Rep; 1972 Apr; 56(2):183-95. PubMed ID: 5043226
[No Abstract] [Full Text] [Related]
15. An overview of the status of the nitrosoureas in other tumors.
Carter SK
Cancer Chemother Rep 3; 1973 May; 4(3):35-46. PubMed ID: 4584034
[No Abstract] [Full Text] [Related]
16. Effects of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU; NSC-79037) and its degradation products on progression of L1210 cells through the cell cycle.
Bray DA; DeVita VT; Adamson RH; Oliverio VT
Cancer Chemother Rep; 1971 Jun; 55(3):215-20. PubMed ID: 5115843
[No Abstract] [Full Text] [Related]
17. Influence of tumor-host differences at a single histocompatibility locus (H-1) on the antileukemic effect of 1,3-bis(2-chloroethyl)-1-nitrosourea (NSC 409962).
Bonmassar E; Cudkowicz G; Vadlamudi S; Goldin A
Cancer Res; 1970 Oct; 30(10):2538-42. PubMed ID: 5474176
[No Abstract] [Full Text] [Related]
18. 1,3-bis(2-chloroethyl)-1-nitrosourea (NSC-409962) and methotrexate (NSC-740) as combination therapy for advanced mouse leukemia L1210.
Venditti JM; Kline I; Tyrer DD; Goldin A
Cancer Chemother Rep; 1965 Oct; 48():35-9. PubMed ID: 5834736
[No Abstract] [Full Text] [Related]
19. The response of human lymphoma cells in vitro to bleomycin and 1,3-bis(2-chloroethyl)-1-nitrosourea.
Drewinko B; Novak JK; Barranco SC
Cancer Res; 1972 Jun; 32(6):1206-8. PubMed ID: 4113143
[No Abstract] [Full Text] [Related]
20. Studies on the chemotherapy of experimental brain tumors: evaluation of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea, vincristine, and 5-fluorouracil.
Shapiro WR
J Natl Cancer Inst; 1971 Feb; 46(2):359-68. PubMed ID: 4256014
[No Abstract] [Full Text] [Related]
[Next] [New Search]
